Cancer Invest. 2013 Oct;31(8):505-10.

Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature.

Van Rite BD, Krais JJ, Cherry M, Sikavitsas VI, Kurkjian C, Harrison RG.

1Bioengineering Center and the School of Chemical, Biological and Materials Engineering, University of Oklahoma , Norman, Oklahoma , USA.

 

Abstract

The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in the tumor, was tested in mice with implanted MBA-MB-231 breast tumors. This therapy was able to cause a reduction in the size of the tumors during the treatment period. It was shown that L-methioninase-annexin V was uniformly bound at the blood vessel surface in the tumor and also that there was a substantial cutoff of blood flowing through the treated tumor, consistent with the therapy’s design. This new approach for enzyme prodrug therapy of breast cancer appears promising.

PMID: 24083814

 

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann